At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine
In Brief
A Phase 3 clinical trial evaluating 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for Pneumococcal Vaccines and Pneumococcal Conjugate Vaccine. Completed, enrolled 764 participants across 8 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine compared to a single dose of 23-valent pneumococcal polysaccharide vaccine in Japanese adults aged 65 years old and older.
Study Details
Timeline
Interventions
A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.